

# Tumor Immunotherapy Market - Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/TFECA19BDAD6EN.html>

Date: March 2022

Pages: 116

Price: US\$ 3,250.00 (Single User License)

ID: TFECA19BDAD6EN

## Abstracts

This report contains market size and forecasts of Tumor Immunotherapy in Global, including the following market information:

Global Tumor Immunotherapy Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Tumor Immunotherapy market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Tumor Infiltrating Lymphocyte (TIL) Treatment Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Tumor Immunotherapy include Roche, Merck, Novartis, Johnson & Johnson, GlaxoSmithKline, AbbVie, ELI Lilly, Amgen and AstraZeneca, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Tumor Immunotherapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Tumor Immunotherapy Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Tumor Immunotherapy Market Segment Percentages, by Type, 2021 (%)

Tumor Infiltrating Lymphocyte (TIL) Treatment

Engineered T Cell Receptor (TCR) Therapy

Chimeric Antigen Receptor (CAR) T Cell Therapy

Natural Killer (NK) Cell Therapy

Other

Global Tumor Immunotherapy Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Tumor Immunotherapy Market Segment Percentages, by Application, 2021 (%)

Biopharmaceutical Company

Hospital

Universities And Other Scientific Research Institutions

Other

Global Tumor Immunotherapy Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Tumor Immunotherapy Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

## Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Tumor Immunotherapy revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Tumor Immunotherapy revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Roche

Merck

Novartis

Johnson & Johnson

GlaxoSmithKline

AbbVie

ELI Lilly

Amgen

AstraZeneca

Bristol-Myers Squibb

Kite Pharma

Adaptimmune

Altor Bioscience Corporation

Collectis

Juno Therapeutics

Takara Bio

Unum Therapeutics

Sunway

Junshi Bio

Cinda Bio

BeiGene

## Contents

### **1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS**

- 1.1 Tumor Immunotherapy Market Definition
- 1.2 Market Segments
  - 1.2.1 Market by Type
  - 1.2.2 Market by Application
- 1.3 Global Tumor Immunotherapy Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
  - 1.5.1 Research Methodology
  - 1.5.2 Research Process
  - 1.5.3 Base Year
  - 1.5.4 Report Assumptions & Caveats

### **2 GLOBAL TUMOR IMMUNOTHERAPY OVERALL MARKET SIZE**

- 2.1 Global Tumor Immunotherapy Market Size: 2021 VS 2028
- 2.2 Global Tumor Immunotherapy Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
  - 2.3.1 Market Opportunities & Trends
  - 2.3.2 Market Drivers
  - 2.3.3 Market Restraints

### **3 COMPANY LANDSCAPE**

- 3.1 Top Tumor Immunotherapy Players in Global Market
- 3.2 Top Global Tumor Immunotherapy Companies Ranked by Revenue
- 3.3 Global Tumor Immunotherapy Revenue by Companies
- 3.4 Top 3 and Top 5 Tumor Immunotherapy Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Tumor Immunotherapy Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Tumor Immunotherapy Players in Global Market
  - 3.6.1 List of Global Tier 1 Tumor Immunotherapy Companies
  - 3.6.2 List of Global Tier 2 and Tier 3 Tumor Immunotherapy Companies

### **4 MARKET SIGHTS BY PRODUCT**

#### 4.1 Overview

4.1.1 by Type - Global Tumor Immunotherapy Market Size Markets, 2021 & 2028

4.1.2 Tumor Infiltrating Lymphocyte (TIL) Treatment

4.1.3 Engineered T Cell Receptor (TCR) Therapy

4.1.4 Chimeric Antigen Receptor (CAR) T Cell Therapy

4.1.5 Natural Killer (NK) Cell Therapy

4.1.6 Other

#### 4.2 By Type - Global Tumor Immunotherapy Revenue & Forecasts

4.2.1 By Type - Global Tumor Immunotherapy Revenue, 2017-2022

4.2.2 By Type - Global Tumor Immunotherapy Revenue, 2023-2028

4.2.3 By Type - Global Tumor Immunotherapy Revenue Market Share, 2017-2028

### 5 SIGHTS BY APPLICATION

#### 5.1 Overview

5.1.1 By Application - Global Tumor Immunotherapy Market Size, 2021 & 2028

5.1.2 Biopharmaceutical Company

5.1.3 Hospital

5.1.4 Universities And Other Scientific Research Institutions

5.1.5 Other

#### 5.2 By Application - Global Tumor Immunotherapy Revenue & Forecasts

5.2.1 By Application - Global Tumor Immunotherapy Revenue, 2017-2022

5.2.2 By Application - Global Tumor Immunotherapy Revenue, 2023-2028

5.2.3 By Application - Global Tumor Immunotherapy Revenue Market Share, 2017-2028

### 6 SIGHTS BY REGION

6.1 By Region - Global Tumor Immunotherapy Market Size, 2021 & 2028

#### 6.2 By Region - Global Tumor Immunotherapy Revenue & Forecasts

6.2.1 By Region - Global Tumor Immunotherapy Revenue, 2017-2022

6.2.2 By Region - Global Tumor Immunotherapy Revenue, 2023-2028

6.2.3 By Region - Global Tumor Immunotherapy Revenue Market Share, 2017-2028

#### 6.3 North America

6.3.1 By Country - North America Tumor Immunotherapy Revenue, 2017-2028

6.3.2 US Tumor Immunotherapy Market Size, 2017-2028

6.3.3 Canada Tumor Immunotherapy Market Size, 2017-2028

6.3.4 Mexico Tumor Immunotherapy Market Size, 2017-2028

#### 6.4 Europe

6.4.1 By Country - Europe Tumor Immunotherapy Revenue, 2017-2028

6.4.2 Germany Tumor Immunotherapy Market Size, 2017-2028

6.4.3 France Tumor Immunotherapy Market Size, 2017-2028

6.4.4 U.K. Tumor Immunotherapy Market Size, 2017-2028

6.4.5 Italy Tumor Immunotherapy Market Size, 2017-2028

6.4.6 Russia Tumor Immunotherapy Market Size, 2017-2028

6.4.7 Nordic Countries Tumor Immunotherapy Market Size, 2017-2028

6.4.8 Benelux Tumor Immunotherapy Market Size, 2017-2028

## 6.5 Asia

6.5.1 By Region - Asia Tumor Immunotherapy Revenue, 2017-2028

6.5.2 China Tumor Immunotherapy Market Size, 2017-2028

6.5.3 Japan Tumor Immunotherapy Market Size, 2017-2028

6.5.4 South Korea Tumor Immunotherapy Market Size, 2017-2028

6.5.5 Southeast Asia Tumor Immunotherapy Market Size, 2017-2028

6.5.6 India Tumor Immunotherapy Market Size, 2017-2028

## 6.6 South America

6.6.1 By Country - South America Tumor Immunotherapy Revenue, 2017-2028

6.6.2 Brazil Tumor Immunotherapy Market Size, 2017-2028

6.6.3 Argentina Tumor Immunotherapy Market Size, 2017-2028

## 6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Tumor Immunotherapy Revenue, 2017-2028

6.7.2 Turkey Tumor Immunotherapy Market Size, 2017-2028

6.7.3 Israel Tumor Immunotherapy Market Size, 2017-2028

6.7.4 Saudi Arabia Tumor Immunotherapy Market Size, 2017-2028

6.7.5 UAE Tumor Immunotherapy Market Size, 2017-2028

## 7 PLAYERS PROFILES

### 7.1 Roche

7.1.1 Roche Corporate Summary

7.1.2 Roche Business Overview

7.1.3 Roche Tumor Immunotherapy Major Product Offerings

7.1.4 Roche Tumor Immunotherapy Revenue in Global Market (2017-2022)

7.1.5 Roche Key News

### 7.2 Merck

7.2.1 Merck Corporate Summary

7.2.2 Merck Business Overview

7.2.3 Merck Tumor Immunotherapy Major Product Offerings

7.2.4 Merck Tumor Immunotherapy Revenue in Global Market (2017-2022)



#### 7.2.5 Merck Key News

### 7.3 Novartis

#### 7.3.1 Novartis Corporate Summary

#### 7.3.2 Novartis Business Overview

#### 7.3.3 Novartis Tumor Immunotherapy Major Product Offerings

#### 7.3.4 Novartis Tumor Immunotherapy Revenue in Global Market (2017-2022)

#### 7.3.5 Novartis Key News

### 7.4 Johnson & Johnson

#### 7.4.1 Johnson & Johnson Corporate Summary

#### 7.4.2 Johnson & Johnson Business Overview

#### 7.4.3 Johnson & Johnson Tumor Immunotherapy Major Product Offerings

#### 7.4.4 Johnson & Johnson Tumor Immunotherapy Revenue in Global Market (2017-2022)

#### 7.4.5 Johnson & Johnson Key News

### 7.5 GlaxoSmithKline

#### 7.5.1 GlaxoSmithKline Corporate Summary

#### 7.5.2 GlaxoSmithKline Business Overview

#### 7.5.3 GlaxoSmithKline Tumor Immunotherapy Major Product Offerings

#### 7.5.4 GlaxoSmithKline Tumor Immunotherapy Revenue in Global Market (2017-2022)

#### 7.5.5 GlaxoSmithKline Key News

### 7.6 AbbVie

#### 7.6.1 AbbVie Corporate Summary

#### 7.6.2 AbbVie Business Overview

#### 7.6.3 AbbVie Tumor Immunotherapy Major Product Offerings

#### 7.6.4 AbbVie Tumor Immunotherapy Revenue in Global Market (2017-2022)

#### 7.6.5 AbbVie Key News

### 7.7 ELI Lilly

#### 7.7.1 ELI Lilly Corporate Summary

#### 7.7.2 ELI Lilly Business Overview

#### 7.7.3 ELI Lilly Tumor Immunotherapy Major Product Offerings

#### 7.7.4 ELI Lilly Tumor Immunotherapy Revenue in Global Market (2017-2022)

#### 7.7.5 ELI Lilly Key News

### 7.8 Amgen

#### 7.8.1 Amgen Corporate Summary

#### 7.8.2 Amgen Business Overview

#### 7.8.3 Amgen Tumor Immunotherapy Major Product Offerings

#### 7.8.4 Amgen Tumor Immunotherapy Revenue in Global Market (2017-2022)

#### 7.8.5 Amgen Key News

### 7.9 AstraZeneca

- 7.9.1 AstraZeneca Corporate Summary
- 7.9.2 AstraZeneca Business Overview
- 7.9.3 AstraZeneca Tumor Immunotherapy Major Product Offerings
- 7.9.4 AstraZeneca Tumor Immunotherapy Revenue in Global Market (2017-2022)
- 7.9.5 AstraZeneca Key News
- 7.10 Bristol-Myers Squibb
  - 7.10.1 Bristol-Myers Squibb Corporate Summary
  - 7.10.2 Bristol-Myers Squibb Business Overview
  - 7.10.3 Bristol-Myers Squibb Tumor Immunotherapy Major Product Offerings
  - 7.10.4 Bristol-Myers Squibb Tumor Immunotherapy Revenue in Global Market (2017-2022)
  - 7.10.5 Bristol-Myers Squibb Key News
- 7.11 Kite Pharma
  - 7.11.1 Kite Pharma Corporate Summary
  - 7.11.2 Kite Pharma Business Overview
  - 7.11.3 Kite Pharma Tumor Immunotherapy Major Product Offerings
  - 7.11.4 Kite Pharma Tumor Immunotherapy Revenue in Global Market (2017-2022)
  - 7.11.5 Kite Pharma Key News
- 7.12 Adaptimmune
  - 7.12.1 Adaptimmune Corporate Summary
  - 7.12.2 Adaptimmune Business Overview
  - 7.12.3 Adaptimmune Tumor Immunotherapy Major Product Offerings
  - 7.12.4 Adaptimmune Tumor Immunotherapy Revenue in Global Market (2017-2022)
  - 7.12.5 Adaptimmune Key News
- 7.13 Altor Bioscience Corporation
  - 7.13.1 Altor Bioscience Corporation Corporate Summary
  - 7.13.2 Altor Bioscience Corporation Business Overview
  - 7.13.3 Altor Bioscience Corporation Tumor Immunotherapy Major Product Offerings
  - 7.13.4 Altor Bioscience Corporation Tumor Immunotherapy Revenue in Global Market (2017-2022)
  - 7.13.5 Altor Bioscience Corporation Key News
- 7.14 Collectis
  - 7.14.1 Collectis Corporate Summary
  - 7.14.2 Collectis Business Overview
  - 7.14.3 Collectis Tumor Immunotherapy Major Product Offerings
  - 7.14.4 Collectis Tumor Immunotherapy Revenue in Global Market (2017-2022)
  - 7.14.5 Collectis Key News
- 7.15 Juno Therapeutics
  - 7.15.1 Juno Therapeutics Corporate Summary

- 7.15.2 Juno Therapeutics Business Overview
- 7.15.3 Juno Therapeutics Tumor Immunotherapy Major Product Offerings
- 7.15.4 Juno Therapeutics Tumor Immunotherapy Revenue in Global Market (2017-2022)
- 7.15.5 Juno Therapeutics Key News
- 7.16 Takara Bio
  - 7.16.1 Takara Bio Corporate Summary
  - 7.16.2 Takara Bio Business Overview
  - 7.16.3 Takara Bio Tumor Immunotherapy Major Product Offerings
  - 7.16.4 Takara Bio Tumor Immunotherapy Revenue in Global Market (2017-2022)
  - 7.16.5 Takara Bio Key News
- 7.17 Unum Therapeutics
  - 7.17.1 Unum Therapeutics Corporate Summary
  - 7.17.2 Unum Therapeutics Business Overview
  - 7.17.3 Unum Therapeutics Tumor Immunotherapy Major Product Offerings
  - 7.17.4 Unum Therapeutics Tumor Immunotherapy Revenue in Global Market (2017-2022)
  - 7.17.5 Unum Therapeutics Key News
- 7.18 Sunway
  - 7.18.1 Sunway Corporate Summary
  - 7.18.2 Sunway Business Overview
  - 7.18.3 Sunway Tumor Immunotherapy Major Product Offerings
  - 7.18.4 Sunway Tumor Immunotherapy Revenue in Global Market (2017-2022)
  - 7.18.5 Sunway Key News
- 7.19 Junshi Bio
  - 7.19.1 Junshi Bio Corporate Summary
  - 7.19.2 Junshi Bio Business Overview
  - 7.19.3 Junshi Bio Tumor Immunotherapy Major Product Offerings
  - 7.19.4 Junshi Bio Tumor Immunotherapy Revenue in Global Market (2017-2022)
  - 7.19.5 Junshi Bio Key News
- 7.20 Cinda Bio
  - 7.20.1 Cinda Bio Corporate Summary
  - 7.20.2 Cinda Bio Business Overview
  - 7.20.3 Cinda Bio Tumor Immunotherapy Major Product Offerings
  - 7.20.4 Cinda Bio Tumor Immunotherapy Revenue in Global Market (2017-2022)
  - 7.20.5 Cinda Bio Key News
- 7.21 BeiGene
  - 7.21.1 BeiGene Corporate Summary
  - 7.21.2 BeiGene Business Overview

- 7.21.3 BeiGene Tumor Immunotherapy Major Product Offerings
- 7.21.4 BeiGene Tumor Immunotherapy Revenue in Global Market (2017-2022)
- 7.21.5 BeiGene Key News

## **8 CONCLUSION**

## **9 APPENDIX**

- 9.1 Note
- 9.2 Examples of Clients
- 9.3 Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1. Tumor Immunotherapy Market Opportunities & Trends in Global Market

Table 2. Tumor Immunotherapy Market Drivers in Global Market

Table 3. Tumor Immunotherapy Market Restraints in Global Market

Table 4. Key Players of Tumor Immunotherapy in Global Market

Table 5. Top Tumor Immunotherapy Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Tumor Immunotherapy Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Tumor Immunotherapy Revenue Share by Companies, 2017-2022

Table 8. Global Companies Tumor Immunotherapy Product Type

Table 9. List of Global Tier 1 Tumor Immunotherapy Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Tumor Immunotherapy Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Tumor Immunotherapy Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Tumor Immunotherapy Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Tumor Immunotherapy Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Tumor Immunotherapy Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Tumor Immunotherapy Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Tumor Immunotherapy Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Tumor Immunotherapy Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Tumor Immunotherapy Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Tumor Immunotherapy Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Tumor Immunotherapy Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Tumor Immunotherapy Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Tumor Immunotherapy Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Tumor Immunotherapy Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Tumor Immunotherapy Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Tumor Immunotherapy Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Tumor Immunotherapy Revenue, (US\$, Mn),

2017-2022

Table 27. By Country - South America Tumor Immunotherapy Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Tumor Immunotherapy Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Tumor Immunotherapy Revenue, (US\$, Mn), 2023-2028

Table 30. Roche Corporate Summary

Table 31. Roche Tumor Immunotherapy Product Offerings

Table 32. Roche Tumor Immunotherapy Revenue (US\$, Mn), (2017-2022)

Table 33. Merck Corporate Summary

Table 34. Merck Tumor Immunotherapy Product Offerings

Table 35. Merck Tumor Immunotherapy Revenue (US\$, Mn), (2017-2022)

Table 36. Novartis Corporate Summary

Table 37. Novartis Tumor Immunotherapy Product Offerings

Table 38. Novartis Tumor Immunotherapy Revenue (US\$, Mn), (2017-2022)

Table 39. Johnson & Johnson Corporate Summary

Table 40. Johnson & Johnson Tumor Immunotherapy Product Offerings

Table 41. Johnson & Johnson Tumor Immunotherapy Revenue (US\$, Mn), (2017-2022)

Table 42. GlaxoSmithKline Corporate Summary

Table 43. GlaxoSmithKline Tumor Immunotherapy Product Offerings

Table 44. GlaxoSmithKline Tumor Immunotherapy Revenue (US\$, Mn), (2017-2022)

Table 45. AbbVie Corporate Summary

Table 46. AbbVie Tumor Immunotherapy Product Offerings

Table 47. AbbVie Tumor Immunotherapy Revenue (US\$, Mn), (2017-2022)

Table 48. ELI Lilly Corporate Summary

Table 49. ELI Lilly Tumor Immunotherapy Product Offerings

Table 50. ELI Lilly Tumor Immunotherapy Revenue (US\$, Mn), (2017-2022)

Table 51. Amgen Corporate Summary

Table 52. Amgen Tumor Immunotherapy Product Offerings

Table 53. Amgen Tumor Immunotherapy Revenue (US\$, Mn), (2017-2022)

Table 54. AstraZeneca Corporate Summary

Table 55. AstraZeneca Tumor Immunotherapy Product Offerings

Table 56. AstraZeneca Tumor Immunotherapy Revenue (US\$, Mn), (2017-2022)

Table 57. Bristol-Myers Squibb Corporate Summary

Table 58. Bristol-Myers Squibb Tumor Immunotherapy Product Offerings

Table 59. Bristol-Myers Squibb Tumor Immunotherapy Revenue (US\$, Mn), (2017-2022)

Table 60. Kite Pharma Corporate Summary

- Table 61. Kite Pharma Tumor Immunotherapy Product Offerings
- Table 62. Kite Pharma Tumor Immunotherapy Revenue (US\$, Mn), (2017-2022)
- Table 63. Adaptimmune Corporate Summary
- Table 64. Adaptimmune Tumor Immunotherapy Product Offerings
- Table 65. Adaptimmune Tumor Immunotherapy Revenue (US\$, Mn), (2017-2022)
- Table 66. Altor Bioscience Corporation Corporate Summary
- Table 67. Altor Bioscience Corporation Tumor Immunotherapy Product Offerings
- Table 68. Altor Bioscience Corporation Tumor Immunotherapy Revenue (US\$, Mn), (2017-2022)
- Table 69. Cellectis Corporate Summary
- Table 70. Cellectis Tumor Immunotherapy Product Offerings
- Table 71. Cellectis Tumor Immunotherapy Revenue (US\$, Mn), (2017-2022)
- Table 72. Juno Therapeutics Corporate Summary
- Table 73. Juno Therapeutics Tumor Immunotherapy Product Offerings
- Table 74. Juno Therapeutics Tumor Immunotherapy Revenue (US\$, Mn), (2017-2022)
- Table 75. Takara Bio Corporate Summary
- Table 76. Takara Bio Tumor Immunotherapy Product Offerings
- Table 77. Takara Bio Tumor Immunotherapy Revenue (US\$, Mn), (2017-2022)
- Table 78. Unum Therapeutics Corporate Summary
- Table 79. Unum Therapeutics Tumor Immunotherapy Product Offerings
- Table 80. Unum Therapeutics Tumor Immunotherapy Revenue (US\$, Mn), (2017-2022)
- Table 81. Sunway Corporate Summary
- Table 82. Sunway Tumor Immunotherapy Product Offerings
- Table 83. Sunway Tumor Immunotherapy Revenue (US\$, Mn), (2017-2022)
- Table 84. Junshi Bio Corporate Summary
- Table 85. Junshi Bio Tumor Immunotherapy Product Offerings
- Table 86. Junshi Bio Tumor Immunotherapy Revenue (US\$, Mn), (2017-2022)
- Table 87. Cinda Bio Corporate Summary
- Table 88. Cinda Bio Tumor Immunotherapy Product Offerings
- Table 89. Cinda Bio Tumor Immunotherapy Revenue (US\$, Mn), (2017-2022)
- Table 90. BeiGene Corporate Summary
- Table 91. BeiGene Tumor Immunotherapy Product Offerings
- Table 92. BeiGene Tumor Immunotherapy Revenue (US\$, Mn), (2017-2022)

## List Of Figures

### LIST OF FIGURES

- Figure 1. Tumor Immunotherapy Segment by Type in 2021
- Figure 2. Tumor Immunotherapy Segment by Application in 2021
- Figure 3. Global Tumor Immunotherapy Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Tumor Immunotherapy Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Tumor Immunotherapy Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Tumor Immunotherapy Revenue in 2021
- Figure 8. By Type - Global Tumor Immunotherapy Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Tumor Immunotherapy Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Tumor Immunotherapy Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Tumor Immunotherapy Revenue Market Share, 2017-2028
- Figure 12. US Tumor Immunotherapy Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Tumor Immunotherapy Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Tumor Immunotherapy Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Tumor Immunotherapy Revenue Market Share, 2017-2028
- Figure 16. Germany Tumor Immunotherapy Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Tumor Immunotherapy Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Tumor Immunotherapy Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Tumor Immunotherapy Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia Tumor Immunotherapy Revenue, (US\$, Mn), 2017-2028
- Figure 21. Nordic Countries Tumor Immunotherapy Revenue, (US\$, Mn), 2017-2028
- Figure 22. Benelux Tumor Immunotherapy Revenue, (US\$, Mn), 2017-2028
- Figure 23. By Region - Asia Tumor Immunotherapy Revenue Market Share, 2017-2028
- Figure 24. China Tumor Immunotherapy Revenue, (US\$, Mn), 2017-2028
- Figure 25. Japan Tumor Immunotherapy Revenue, (US\$, Mn), 2017-2028
- Figure 26. South Korea Tumor Immunotherapy Revenue, (US\$, Mn), 2017-2028
- Figure 27. Southeast Asia Tumor Immunotherapy Revenue, (US\$, Mn), 2017-2028
- Figure 28. India Tumor Immunotherapy Revenue, (US\$, Mn), 2017-2028
- Figure 29. By Country - South America Tumor Immunotherapy Revenue Market Share, 2017-2028



- Figure 30. Brazil Tumor Immunotherapy Revenue, (US\$, Mn), 2017-2028
- Figure 31. Argentina Tumor Immunotherapy Revenue, (US\$, Mn), 2017-2028
- Figure 32. By Country - Middle East & Africa Tumor Immunotherapy Revenue Market Share, 2017-2028
- Figure 33. Turkey Tumor Immunotherapy Revenue, (US\$, Mn), 2017-2028
- Figure 34. Israel Tumor Immunotherapy Revenue, (US\$, Mn), 2017-2028
- Figure 35. Saudi Arabia Tumor Immunotherapy Revenue, (US\$, Mn), 2017-2028
- Figure 36. UAE Tumor Immunotherapy Revenue, (US\$, Mn), 2017-2028
- Figure 37. Roche Tumor Immunotherapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)
- Figure 38. Merck Tumor Immunotherapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)
- Figure 39. Novartis Tumor Immunotherapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)
- Figure 40. Johnson & Johnson Tumor Immunotherapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)
- Figure 41. GlaxoSmithKline Tumor Immunotherapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)
- Figure 42. AbbVie Tumor Immunotherapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)
- Figure 43. ELI Lilly Tumor Immunotherapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)
- Figure 44. Amgen Tumor Immunotherapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)
- Figure 45. AstraZeneca Tumor Immunotherapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)
- Figure 46. Bristol-Myers Squibb Tumor Immunotherapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)
- Figure 47. Kite Pharma Tumor Immunotherapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)
- Figure 48. Adaptimmune Tumor Immunotherapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)
- Figure 49. Altor Bioscience Corporation Tumor Immunotherapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)
- Figure 50. Cellectis Tumor Immunotherapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)
- Figure 51. Juno Therapeutics Tumor Immunotherapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)
- Figure 52. Takara Bio Tumor Immunotherapy Revenue Year Over Year Growth (US\$,

Mn) & (2017-2022)

Figure 53. Unum Therapeutics Tumor Immunotherapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 54. Sunway Tumor Immunotherapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 55. Junshi Bio Tumor Immunotherapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 56. Cinda Bio Tumor Immunotherapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 57. BeiGene Tumor Immunotherapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

## I would like to order

Product name: Tumor Immunotherapy Market - Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/TFECA19BDAD6EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TFECA19BDAD6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970